Form 4: Bio-Rad Laboratories Chairman and CEO Norman Schwartz Reports Stock Option Grant

Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, reports the acquisition of stock options and changes in beneficial ownership of company stock.

Summary

• Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The report includes the acquisition of 11,671 non-qualified stock options with an exercise price of $256.45, exercisable starting March 3, 2025, and expiring on March 3, 2035.
• The stock options vest over four years at 25% per year on the yearly anniversary date of the grant.
• Schwartz also reported direct ownership of 438,238 shares of Bio-Rad A Common Stock and 361,466 shares of Bio-Rad B Common Stock.
• Indirect ownership includes 13,006 shares of Bio-Rad B Common Stock held by his spouse and 4,060,054 shares held by Blue Raven Partners, L.P., where Schwartz is a limited and general partner.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and insider ownership, suggesting confidence in the company's future.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.

Future Outlook

The vesting schedule of the stock options suggests a long-term commitment from the executive to the company's success.

Management Comments

• The reporting person disclaims beneficial ownership of shares held by his spouse and Blue Raven Partners, L.P., except to the extent of his pecuniary interest.

Industry Context

Executive compensation packages often include stock options to align management's interests with shareholder value, a common practice in the biotechnology and life sciences industry.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the biotech industry, often benchmarked against peer companies like Danaher, Thermo Fisher Scientific, and Agilent Technologies.
• The vesting schedule and exercise price are typical considerations in structuring these grants to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing management to increase company value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates